Alpagat, GulistanBaccıoğlu, AyseYalim, Sumeyra AlanPoyraz, MerveDumanoğlu, BetulKalpaklıoğlu, Ayse Fusun2025-01-212025-01-2120222147-2475https://doi.org/10.5505/respircase.2022.80948https://search.trdizin.gov.tr/tr/yayin/detay/517411https://hdl.handle.net/20.500.12587/22994It is accepted that 2–3% of interstitial lung diseases (ILD) are due to drugs, and that 70% of drug-induced lung diseases are due to ILD. We present here the case of a 51-year-old female patient who had been taking aripiprazole for bipolar disorder for 3 years and had been undergoing asthma treatment for 2 years. ILD was considered based on the patient's clinic, a restrictive pattern in the pulmonary function test (PFT), a decreased carbon monoxide diffusion test, laboratory results, radiological findings and biopsy. The possible etiologies of infection, aspiration, heart failure, pet feeding status and exposure to haz-ardous respiratory substances were excluded. The suspected drug was discontinued and oral cortico-steroid treatment was started. Lung toxicity can devel-op with drug treatments, and so drug history should be questioned in detail and discontinued immediately in case of any doubt. ILD is rare, and if the drug is not suspected and continued, the disease may be-come chronic and progress to respiratory failure. We present this case to increase awareness of the disease.eninfo:eu-repo/semantics/openAccessSolunum SistemiGenel ve Dahili TıpArticle111444910.5505/respircase.2022.80948517411